NeuroSense Therapeutics Ltd. (H1Z)

Overview

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company engaged in the discovery and development of treatments aimed at addressing the challenges of neurodegenerative diseases on a global scale. Established in 2017 and based in Herzliya, Israel, the company operates both in the United States and internationally, working towards creating impactful therapies for patients suffering from conditions that currently have limited effective treatment options. NeuroSense Therapeutics is dedicated to improving the lives of individuals affected by debilitating neurological conditions through innovative research and therapeutic development.

Products and Services

• PrimeC

  An extended-release oral formulation that combines ciprofloxacin and celecoxib into a fixed-dose combination. PrimeC is primarily under investigation for its use in treating amyotrophic lateral sclerosis (ALS) and is currently at the Phase 2b/3 clinical trial stage. Additionally, it has completed Phase 2 clinical trials for the treatment of Alzheimer's disease and is undergoing preclinical studies for its potential application in treating Parkinson's disease. PrimeC exemplifies the company's focus on developing treatments that can address multiple neurodegenerative diseases with a single therapeutic approach.

• StabiliC

  Currently in the preclinical development phase, StabiliC is being explored for its potential to treat Parkinson's disease. This investigational product represents NeuroSense Therapeutics' commitment to expanding its pipeline and exploring innovative therapies for neurodegenerative diseases, particularly targeting the debilitating effects of Parkinson's disease with novel therapeutic strategies.

• CogniC

  Another promising candidate in the company's preclinical pipeline, CogniC, is under investigation for the treatment of Alzheimer's disease. This initiative reflects NeuroSense Therapeutics' continued efforts to address the complex challenges associated with Alzheimer's through the development of targeted treatments aimed at alleviating symptoms and potentially slowing the progression of the disease.